Literature DB >> 11916606

Percutaneous septal ablation for hypertrophic cardiomyopathy and mid-ventricular obstruction.

H Seggewiss1, L Faber.   

Abstract

AIMS: Percutaneous transluminal septal myocardial ablation by alcohol-induced septal branch occlusion is a new treatment option in symptomatic patients with hypertrophic cardiomyopathy and subaortic, SAM-associated obstruction. We report on a patient with mid-ventricular obstruction and echocardiographic-guided reduction of septal hypertrophy. METHODS AND
RESULTS: A 52-year-old woman with NYHA class III and recurrent exercise-induced syncope suffered from hypertrophic cardiomyopathy with mid-ventricular obstruction. She had a systolic gradient of 71 mmHg at rest and 153 mmHg post-extrasystole, and diastolic inflow gradient of 20 mmHg. Echo-guided percutaneous transluminal septal myocardial ablation with occlusion of the fourth septal branch resulted in acute reduction and final elimination of systolic, as well as diastolic resting and provocable gradients. Complications were not seen. At 3 months' follow-up the patient was asymptomatic and without further syncopes.
CONCLUSIONS: Echocardiographic-guided percutaneous transluminal septal myocardial ablation is able to reduce gradients in hypertrophic cardiomyopathy and mid-ventricular obstruction with consecutive improvement of symptoms.

Entities:  

Mesh:

Year:  2000        PMID: 11916606     DOI: 10.1053/euje.2000.0032

Source DB:  PubMed          Journal:  Eur J Echocardiogr        ISSN: 1532-2114


  15 in total

Review 1.  Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy.

Authors:  H Seggewiss
Journal:  Curr Cardiol Rep       Date:  2001-03       Impact factor: 2.931

Review 2.  Transcatheter septal ablation in hypertrophic obstructive cardiomyopathy: a technical guide and review of published results.

Authors:  Angelos G Rigopoulos; Stefanos Sakellaropoulos; Muhammad Ali; Sophie Mavrogeni; Athanassios Manginas; Matthias Pauschinger; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2018-11       Impact factor: 4.214

3.  Percutaneous myocardial ablation for left mid-ventricular obstructive hypertrophic cardiomyopathy.

Authors:  I Tengiz; E Ercan; U O Türk
Journal:  Int J Cardiovasc Imaging       Date:  2005-12-12       Impact factor: 2.357

4.  Percutaneous septal ablation: a new treatment for hypertrophic obstructive cardiomyopathy.

Authors:  H Seggewiss
Journal:  Neth Heart J       Date:  2001-11       Impact factor: 2.380

Review 5.  Surgical treatment for hypertrophic cardiomyopathy: a historical perspective.

Authors:  Dustin Hang; Anita Nguyen; Hartzell V Schaff
Journal:  Ann Cardiothorac Surg       Date:  2017-07

6.  Ventricular tachycardia and heart failure in a patient of mid-ventricular obstructive hypertrophic cardiomyopathy with apical aneurysm: A case report.

Authors:  Xin Zhang; Xingbin Liu
Journal:  Exp Ther Med       Date:  2019-07-19       Impact factor: 2.447

Review 7.  Hypertrophic Obstructive Cardiomyopathy.

Authors:  Angelika Batzner; Hans-Joachim Schäfers; Konstantin V Borisov; Hubert Seggewiß
Journal:  Dtsch Arztebl Int       Date:  2019-01-25       Impact factor: 5.594

8.  Mid-ventricular obstructive hypertrophic cardiomyopathy associated with an apical aneurysm: evaluation of possible causes of aneurysm formation.

Authors:  Yuichi Sato; Naoya Matsumoto; Shinro Matsuo; Shunichi Yoda; Shigemasa Tani; Yuji Kasamaki; Tadateru Takayama; Satoshi Kunimoto; Satoshi Saito
Journal:  Yonsei Med J       Date:  2007-10-31       Impact factor: 2.759

9.  Mid-ventricular hypertrophic obstructive cardiomyopathy presenting with acute myocardial infarction.

Authors:  Yuichi Sato; Naoya Matsumoto; Shinro Matsuo; Shunichi Yoda; Satoshi Kunimoto; Satoshi Saito
Journal:  Tex Heart Inst J       Date:  2007

10.  Alcohol Septal Ablation for the Treatment of Hypertrophic Obstructive Cardiomyopathy.

Authors:  Constantinos O'Mahony; Saidi A Mohiddin; Charles Knight
Journal:  Interv Cardiol       Date:  2014-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.